Taiho Ventures has supplied a $10m extension for Caltech spinout Axial Biotherapeutics’ series B, bringing the total to $35m.

Axial Biotherapeutics, a US-based biotechnology developer spun out of California Institute of Technology (Caltech), boosted its series B round to $35m on Thursday following a $10m extension provided by pharmaceutical firm Taiho.
Taiho supplied the money through its corporate venturing arm, Taiho Ventures. Axial closed an initial $25m tranche in February 2019 led by Health for Life Capital, a fund managed by Seventure Partners, with participation from healthcare provider Heritage Medical Systems.
Investment management firms Longwood Fund…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in